SavedAdd your journal

Journals / Laparoscopic Endoscopic Surgical Science / 2021 / Cilt: 28 - Sayı: 4

Factor to consider in gastroesophageal reflux disease refractory to proton pump inhibitor therapy: Bile reflux

Celil UĞURLU
Mustafa Sami BOSTAN
Pages
187–191
Publication Date
2022-09-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When BR and the presence of Helicobacter pylori were compared, it was found that BR was higher in patients who were refractory to PPI therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: We aimed to investigate the effect of bile reflux (BR) in patients whose symptoms did not improve despite proton pump inhibitor (PPI) treatment.
📊
Key Findings & Data:Results: A total of 154 patients were included in the study.
💡
Conclusion & Impact:When BR and the presence of Helicobacter pylori were compared, it was found that BR was higher in patients who were refractory to PPI therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: We aimed to investigate the effect of bile reflux (BR) in patients whose symptoms did not improve despite proton pump inhibitor (PPI) treatment. Materials and Methods: In our retrospective study, patients who were refractory to PPI treatment were divided into two groups as BR and non-BR patients based on the upper gastrointestinal endoscopy and endoscopic biopsy data. Age, sex, and endoscopic biopsy data of the patients were analyzed statistically. Results: A total of 154 patients were included in the study. BR was detected in 107 of the patients, while BR was not observed in 47. While, 53% (n=81) of the patients were male and 47% (n=73) were female. There was no statistically significant difference between the two groups in terms of age, sex, and endoscopic biopsy data. When BR and the presence of Helicobacter pylori were compared, it was found that BR was higher in patients who were refractory to PPI therapy. Conclusion: We believe that BR is a more effective factor than H. pylori in PPI-refractory gastroesophageal reflux patients.

🔖

Cite This Article

UĞURLU, C., BOSTAN, M. S. (2022). Factor to consider in gastroesophageal reflux disease refractory to proton pump inhibitor therapy: Bile reflux. Laparoscopic Endoscopic Surgical Science, Cilt: 28 - Sayı: 4, 187–191. https://ajindex.com/articles/423561

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Niu XP, Yu BP, Wang YD, Han Z, Liu SF, He CY, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol 2013;19:3124–9
  2. Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011;17:387–94
  3. Jung DH, Huh CW, Lee SK, Park JC, Shin SK, Lee YC. A Systematic review and meta-analysis of randomized control trials: combination treatment with proton pump ınhibitor plus prokinetic for gastroesophageal reflux disease. J Neurogastroenterol Motil 2021;27:165–75
  4. Iwakiri K, Sano H, Tanaka Y, Kawami N, Umezawa M, Futagami S, et al. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy. Digestion 2010;82:156–61
  5. Sasaki CT, Doukas SG, Doukas PG, Vageli DP. Weakly acidic bile ıs a risk factor for hypopharyngeal carcinogenesis evidenced by DNA damage, antiapoptotic function, and premalignant dysplastic lesions in vivo. Cancers (Basel) 2021;13:852
  6. Vyas M, Celli R, Singh M, Patel N, Aslanian HR, Boffa D, et al. Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction. Hum Pathol 2020;105:67–73
  7. Zhang LY, Zhang J, Li D, Liu Y, Zhang DL, Liu CF, et al. Bile reflux is an independent risk factor for precancerous gastric lesions and gastric cancer: An observational cross-sectional study. J Dig Dis 2021;22:282–90
  8. Li D, Zhang J, Yao WZ, Zhang DL, Feng CC, He Q, et al. The relationship between gastric cancer, its precancerous lesions and bile reflux: A retrospective study. J Dig Dis 2020;21:222–9
  9. Fall K, Ye W, Nyrén O. Risk for gastric cancer after cholecystectomy. Am J Gastroenterol 2007;102:1180–4
  10. Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004;99:981–8
  11. Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol 2018;11:119– 34
  12. Savarino V, Marabotto E, Zentilin P, De